Haddad, Robert <br/><br/>
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.  [electronic resource] 

 -  Journal of medical economics  May 2020 
 - 442-447 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2020.1715414  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--adverse effects<br/>Cost-Benefit Analysis<br/>Head and Neck Neoplasms--drug therapy<br/>Humans<br/>Models, Economic<br/>Neoplasm Recurrence, Local<br/>Nivolumab--adverse effects<br/>Quality-Adjusted Life Years<br/>Squamous Cell Carcinoma of Head and Neck--drug therapy<br/>Survival Analysis<br/>United States